76 results about "Dextromethorphan" patented technology

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Methods and compositions for treating pain are provided. Methods for treating pain include administering an effective amount of dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor to a subject in need thereof. Compositions for treating pain that include dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor are administered to a subject in need thereof.

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.

The present application provides a detection method and quality control method for related substances in dextromethorphan oral solution, which comprises the following steps: dissolving dextromethorphan oral solution in a solvent to obtain a test solution; and performing high performance liquid chromatography detection on the test solution; the mobile phase used in the high performance liquid chromatography detection comprises mobile phase A and mobile phase B, the mobile phase A comprises a phosphate solution, the mobile phase B comprises acetonitrile, and the concentration of the phosphate solution is 0.1 mM-10 mM. The detection method has good linear relationship between dextromethorphan and related substances, good accuracy and sensitivity, strong specificity, high stability, good separation degree and good reproducibility, and is suitable for wide application.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

The invention relates to the technical field of organic synthesis, in particular to a refining method of a crude product of dextroborneol, which comprises the following steps: sequentially carrying out a rearrangement reaction, an esterification reaction, a salt forming reaction, an alkaline hydrolysis reaction and post-treatment refining on the crude product of dextroborneol in the presence of a solvent and a catalyst on the basis of a reaction product to obtain a refined product of dextroborneol, in the refined dextroborneol product, the content of dextroborneol is greater than or equal to 98.0%, the content of L-borneol is less than or equal to 1.0%, the content of isoborneol is less than or equal to 0.15%, the content of natural camphor is less than or equal to 0.15%, and the content of other impurities is less than or equal to 0.10%. The method has the advantages that the isoborneol structure can be selectively destroyed under mild conditions, impurities are effectively removed through the esterification-salification-alkaline hydrolysis three-step reaction, and the purity and yield of dextroborneol are remarkably improved.

Methods and compositions for treating pain are provided. Methods for treating pain include administering an effective amount of dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor to a subject in need thereof. Compositions for treating pain that include dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor are administered to a subject in need thereof.

The present invention provides a pharmaceutical composition comprising dextromethorphan, the composition comprising dextromethorphan or a pharmaceutically acceptable salt thereof, and fluoxetine or a pharmaceutically acceptable salt thereof. According to the pharmaceutical composition provided by the invention, the dextromethorphan or the pharmaceutically acceptable salt of the dextromethorphan and the fluoxetine or the pharmaceutically acceptable salt of the fluoxetine are combined according to a specific proportion, so that the pharmaceutical composition not only has an excellent synergistic effect, but also reduces the dosage of the dextromethorphan and the fluoxetine which are independently used. The invention also provides application of the pharmaceutical composition in preparation of drugs for preventing and / or treating cough and neuropsychiatric disorders, especially depression.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

This invention provides an imine reductase mutant, its preparation method, and its application in the catalytic preparation of dextromethorphan intermediates. The imine reductase mutant is an imine reductase with an amino acid mutation, comprising the amino acid sequence shown in SEQ ID NO:1. The amino acid mutation type includes any one or a combination of at least two of I122T, D212A, or G228R. By introducing a mutation into the imine reductase, this invention significantly improves the enzyme's activity and stereoselectivity, enabling the high-yield synthesis of the dextromethorphan intermediate (S)-1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline under mild conditions, greatly reducing production costs and making it suitable for industrial production.

Disclosed herein is a method of treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and are CYP2D6 poor metabolizers.

The invention discloses an atomizing agent applied to an atomizer and capable of relieving dry cough and a preparation method of the atomizing agent. The effective components comprise the following raw materials: bulbus fritillariae cirrhosae extract, folium eriobotryae extract, radix asteris extract, rhizoma pinelliae extract, radix ophiopogonis extract, herba ephedrae extract, honeysuckle flower extract, radix scutellariae extract, liquorice root extract, dextromethorphan and budesonide. The atomizing agent disclosed by the invention has a good treatment effect on respiratory system disease patients with dry cough without phlegm or less phlegm symptoms, has the effects of moistening lung to arrest cough, reducing phlegm and relieving asthma, resisting inflammation and the like, and can be applied to atomizers.

An object of the present invention to provide a clozapine-induced sialorrhea alleviator. The clozapine-induced sialorrhea alleviator of the present invention contains as an active ingredient dextromethorphan, a compound having an antagonistic action on an NMDA-type glutamate receptor, or a compound having an agonistic action on a sigma-1 receptor.

The invention discloses solid particles of edaravone and dextroborneol prepared by a wet granulation process and a solid oral quick-release preparation prepared from the solid particles. The solid particles comprise edaravone, dextroborneol, polyethylene glycol and other pharmaceutic adjuvants. According to the present invention, the dextroborneol and the polyethylene glycol are co-dissolved in the absolute ethyl alcohol, and the wet granulation is performed with the edaravone and the pharmaceutical excipients, such that the process feasibility is significantly improved, and the particles with different particle sizes can be prepared according to the absolute ethyl alcohol use amount so as to prepare the oral quick-release tablets with different dosage forms, the dissolving-out speed of the prepared solid particle dextroborneol is obviously improved, and the stability of edaravone is also improved at the same time.

To provide a solid composition which suppresses decline in the content of loratadine over time even when containing ibuprofen and loratadine.SOLUTION: A solid composition comprises (a) ibuprofen and (b) loratadine and further (c) at least one kind selected from the group consisting of bromhexine and salts thereof, a tranexamic acid, a glycyrrhizic acid and salts thereof, tipepidine and salts thereof, and dextromethorphan and salts thereof.SELECTED DRAWING: None

1. Name of the product of this design: Packaging box (Idarubicin and Dextromethorphan Sublingual Tablets - Xinbixin). 2. Purpose of this design product: This design product is used for pharmaceutical packaging. 3. The key design points of this product are the combination of shape, pattern and color. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The design for which protection is sought includes color.

The invention relates to the technical field of drug detection, in particular to an environment drug detection and collection reagent and a use method thereof.The environment drug detection and collection reagent comprises 0.05%-5% of a preservative, 0.5%-10% of a scale inhibitor, 0.1%-5% of a surfactant and a pH regulator; the pH value of the drug detection and collection reagent in the environment is 6.5-8.5; the detection and collection reagent for the drugs in the environment is wide in application range, and can be suitable for rapid collection and detection of the drugs such as morphine, methamphetamine, ketamine, cocaine, cannabis sativa, ecaloin, etomidate and dextromethorphan. The drug detection and collection reagent can effectively reduce the detection threshold value of a high-sensitivity detection plate, further improves the sensitivity of drug detection and analysis, and is suitable for further popularization and application.